Diefenbach Michael A, Mohamed Nihal E
Department of Urology and Oncological Science, The Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York 10029, USA.
Cancer Invest. 2007 Sep;25(6):449-57. doi: 10.1080/07357900701359460.
We examined decisional regret among prostate cancer patients and its association with disease-specific quality of life. Patients (N = 793) completed questionnaires at diagnosis, at 6 months, and 12 months thereafter. Although levels of decisional regret were low, regret increased significantly between 6 and 12 months after diagnosis. The increase was substantial for patients treated with prostatectomy compared to patients treated with external beam radiation or brachytherapy. Cross-sectional, significant, and positive associations among regret, activity limitation attributed to urinary dysfunction, and bother with sexual and urinary dysfunction emerged. Longitudinally, the change in the level of regret was significantly associated with treatment modality and with the change in bother with sexual dysfunction over the first 6 months after diagnosis. Extensive discussions about disease-specific quality of life should be included when physicians counsel patients about treatment options.
我们研究了前列腺癌患者的决策性遗憾及其与疾病特异性生活质量的关联。患者(N = 793)在确诊时、6个月时以及此后的12个月时完成问卷调查。尽管决策性遗憾水平较低,但在确诊后6至12个月期间,遗憾感显著增加。与接受外照射放疗或近距离放疗的患者相比,接受前列腺切除术的患者遗憾感增加幅度更大。遗憾、归因于排尿功能障碍的活动受限以及性和排尿功能障碍困扰之间出现了横断面显著的正相关。纵向来看,遗憾水平的变化与治疗方式以及确诊后前6个月内性功能障碍困扰的变化显著相关。当医生就治疗选择向患者提供咨询时,应纳入关于疾病特异性生活质量的广泛讨论。